Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
Patients with Colorectal Cancer
Colorectal Cancer Research at NIH
This study will determine whether Pexastimogene Devacirepvec (Pexa-Vec), given in combination with Durvalumab, will cause tumors to shrink. Pexa-Vec is a vaccine used to help boost the immune system to attack and destroy the cancer cells in patients. Durvalumab targets PDL-1, a protein found on tumor cells that contributes to the tumors avoidance of the immune system.
- Physical examination and questionnaire
- Imaging assessments (computed tomographic scan (CT) or magnetic resonance imaging (MRI))
- Study treatment will be divided into cycles each lasting approximately 28 days
- Patients must have progressed on, been intolerant of, or refused prior treatment
- Patients must have at least one focus of metastatic disease
- Patient able to provide a tumor sample from a previous surgery to confirm patient's diagnosis. If a sample is not available, patient will need to have a biopsy of your tumor
The NIH Clinical Center is America's Research Hospital and is located in Bethesda, Maryland, on the Metro Red line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
800-877-8339 TTY / ASCII
Se habla español
Or go online:
Refer to NIH study # 17-C-0092
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Print the Flyer
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/09/2020